Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
|Videos|July 3, 2017
Is One Immunotherapy for Lung Cancer Better Than the Rest?
Author(s)Melissa L. Johnson, MD
This video reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy.
Advertisement
In this video, Melissa L. Johnson, MD, of Sarah Cannon Research Institute in Nashville, Tennessee, reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy and highlights upcoming research in this setting.
Johnson gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting last month in Chicago.
Advertisement
Related to this article
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
3
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
4
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
5